Phase 1b/2a in SLE With Budoputug

Status:
WITHDRAWN

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of budoprutug in participants with SLE

PHASE1

Tenet Medicines